|
1
|
Röllig C, Knop S and Bornhäuser M:
Multiple myeloma. Lancet. 385:2197–2208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kunacheewa C and Orlowski RZ: New drugs in
multiple myeloma. Annu Rev Med. 70:521–547. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pinto V, Bergantim R, Caires HR, Seca H,
Guimãraes JE and Vasconcelos MH: Multiple myeloma: Available
therapies and causes of drug resistance. Cancers (Basel).
12:4072020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pawlyn C and Davies FE: Toward
personalized treatment in multiple myeloma based on molecular
characteristics. Blood. 133:660–675. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jamal M, Song T, Chen B, Faisal M, Hong Z,
Xie T, Wu Y, Pan S, Yin Q, Shao L and Zhang Q: Recent progress on
circular RNA research in acute myeloid leukemia. Front Oncol.
9:11082019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kristensen LS, Andersen MS, Stagsted LV,
Ebbesen KK, Hansen TB and Kjems J: The biogenesis, biology and
characterization of circular RNAs. Nat Rev Genet. 20:675–691. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Z, Sun H, Li J and Jin H: Circular RNAs
in leukemia. Aging (Albany NY). 11:4757–4771. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li W, Zhong C, Jiao J, Li P, Cui B, Ji C
and Ma D: Characterization of hsa_circ_0004277 as a new biomarker
for acute myeloid leukemia via circular RNA profile and
bioinformatics analysis. Int J Mol Sci. 18:5972017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lv C, Sun L, Guo Z, Li H, Kong D, Xu B,
Lin L, Liu T, Guo D, Zhou J and Li Y: Circular RNA regulatory
network reveals cell-cell crosstalk in acute myeloid leukemia
extramedullary infiltration. J Transl Med. 16:3612018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ding Y, Dong Y, Lu H, Luo X, Fu J, Xiu B,
Liang A and Zhang W: Circular RNA profile of acute myeloid
leukaemia indicates circular RNA annexin A2 as a potential
biomarker and therapeutic target for acute myeloid leukaemia. Am J
Transl Res. 12:1683–1699. 2020.PubMed/NCBI
|
|
11
|
Liu X, Tang H, Liu J and Wang X:
hsa_circRNA_101237: A novel diagnostic and prognostic biomarker and
potential therapeutic target for multiple myeloma. Cancer Manag
Res. 12:2109–2118. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou F, Wang D, Wei W, Chen H, Shi H, Zhou
N, Wu L and Peng R: Comprehensive profiling of circular RNA
expressions reveals potential diagnostic and prognostic biomarkers
in multiple myeloma. BMC Cancer. 20:402020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rajkumar SV, Dimopoulos MA, Palumbo A,
Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E,
Richardson P, et al: International myeloma working group updated
criteria for the diagnosis of multiple myeloma. Lancet Oncol.
15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chinese Hematology Association and Chinese
Society of Hematology, . Zhonghua Nei Ke Za Zhi. 61:480–487.
2022.(Article in Chinese). PubMed/NCBI
|
|
15
|
Ludwig H, Miguel JS, Dimopoulos MA,
Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J,
Jurczyszyn A, et al: International myeloma working group
recommendations for global myeloma care. Leukemia. 28:981–992.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rajkumar SV, Harousseau JL, Durie B,
Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski
R, Siegel D, et al: Consensus recommendations for the uniform
reporting of clinical trials: Report of the international myeloma
workshop consensus panel 1. Blood. 117:4691–4695. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Durie BG, Harousseau JL, Miguel JS, Bladé
J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J,
Sonneveld P, et al: International uniform response criteria for
multiple myeloma. Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Skuja E, Butane D, Nakazawa-Miklasevica M,
Daneberga Z, Purkalne G and Miklasevics E: Deletions in metastatic
colorectal cancer with chromothripsis. Exp Oncol. 41:323–327.
2019.PubMed/NCBI
|
|
19
|
Wang L, Liu X, Yue M, Liu Z, Zhang Y, Ma
Y, Luo J, Li W, Bai J, Yao H, et al: Identification of hub genes in
bladder cancer based on weighted gene co-expression network
analysis from TCGA database. Cancer Rep (Hoboken).
e15572021.(Online ahead of print). PubMed/NCBI
|
|
20
|
Cheng Q and Wang L: LncRNA XIST serves as
a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in
kidney transplant acute kidney injury via sponging hsa-miR-212-3p
and hsa-miR-122-5p. Cell Cycle. 19:290–299. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou Y, Liu X, Xue J, Liu L, Liang T, Li
W, Yang X, Hou X and Fang H: Discovery of peptide boronate
derivatives as histone deacetylase and proteasome dual inhibitors
for overcoming bortezomib resistance of multiple myeloma. J Med
Chem. 63:4701–4715. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Zhang W, Wang Y and Wang S:
HOXD-AS1 promotes cell proliferation, migration and invasion
through miR-608/FZD4 axis in ovarian cancer. Am J Cancer Res.
8:170–182. 2018.PubMed/NCBI
|
|
23
|
Jin Y, Xu L, Wu X, Feng J, Shu M, Gu H,
Gao G, Zhang J, Dong B and Chen X: Synergistic efficacy of the
demethylation agent decitabine in combination with the protease
inhibitor bortezomib for treating multiple myeloma through the
Wnt/β-catenin pathway. Oncol Res. 27:729–737. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yao R, Sun X, Xie Y, Liu L, Han D, Yao Y,
Li H, Li Z and Xu K: Lithium chloride inhibits cell survival,
overcomes drug resistance, and triggers apoptosis in multiple
myeloma via activation of the Wnt/β-catenin pathway. Am J Transl
Res. 10:2610–2618. 2018.PubMed/NCBI
|
|
25
|
Savvidou I, Khong T, Cuddihy A, McLean C,
Horrigan S and Spencer A: β-catenin inhibitor BC2059 is efficacious
as monotherapy or in combination with proteasome inhibitor
bortezomib in multiple myeloma. Mol Cancer Ther. 16:1765–1778.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen X, Mao R, Su W, Yang X, Geng Q, Guo
C, Wang Z, Wang J, Kresty LA, Beer DG, et al: Circular RNA
circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKα
signaling in STK11 mutant lung cancer. Autophagy. 16:659–671. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fang Y, Wang X, Li W, Han J, Jin J, Su F,
Zhang J, Huang W, Xiao F, Pan Q and Zou L: Screening of circular
RNAs and validation of circANKRD36 associated with inflammation in
patients with type 2 diabetes mellitus. Int J Mol Med.
42:1865–1874. 2018.PubMed/NCBI
|
|
29
|
Zhang M, Wen F and Zhao K: Circular
RNA_0001946 is insufficiently expressed in tumor tissues, while its
higher expression correlates with less lymph node metastasis, lower
TNM stage, and improved prognosis in NSCLC patients. J Clin Lab
Anal. 35:e236252021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gajos-Michniewicz A and Czyz M: WNT
signaling in melanoma. Int J Mol Sci. 21:48522020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van Andel H, Kocemba KA, Spaargaren M and
Pals ST: Aberrant Wnt signaling in multiple myeloma: Molecular
mechanisms and targeting options. Leukemia. 33:1063–1075. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peterson TR, Laplante M, Thoreen CC,
Sancak Y, Kang SA, Kuehl WM, Gray NS and Sabatini DM: DEPTOR is an
mTOR inhibitor frequently overexpressed in multiple myeloma cells
and required for their survival. Cell. 137:873–886. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li J, Zhu J, Cao B and Mao X: The mTOR
signaling pathway is an emerging therapeutic target in multiple
myeloma. Curr Pharm Des. 20:125–135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Podar K, Chauhan D and Anderson KC: Bone
marrow microenvironment and the identification of new targets for
myeloma therapy. Leukemia. 23:10–24. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu TH, Huang CC, Lin PR, Chang HW, Ger LP,
Lin YW, Changchien CS, Lee CM and Tai MH: Expression and prognostic
role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular
carcinoma. Cancer. 97:1929–1940. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie Y, Du J, Liu Z, Zhang D, Yao X and
Yang Y: MiR-6875-3p promotes the proliferation, invasion and
metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway. J
Exp Clin Cancer Res. 38:72019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gupta S, Iljin K, Sara H, Mpindi JP,
Mirtti T, Vainio P, Rantala J, Alanen K, Nees M and Kallioniemi O:
FZD4 as a mediator of ERG oncogene-induced WNT signaling and
epithelial-to-mesenchymal transition in human prostate cancer
cells. Cancer Res. 70:6735–6745. 2010. View Article : Google Scholar : PubMed/NCBI
|
